{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-077865","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.999257+00:00","generated_at":"2026-05-20T10:48:45.384405+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","bullets":["Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.","Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.","Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.","Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-077865","json":"https://secwatch.observer/filing/0000950170-25-077865.json","markdown":"https://secwatch.observer/filing/0000950170-25-077865.md","text":"https://secwatch.observer/filing/0000950170-25-077865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/0000950170-25-077865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/vktx-20250520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:48:45.384405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}